ImmunityBio (NASDAQ:IBRX) Shares Gap Down – Here’s What Happened

ImmunityBio, Inc. (NASDAQ:IBRX) shares gapped down prior to trading on Tuesday . The stock had previously closed at $6.21, but opened at $5.96. ImmunityBio shares last traded at $5.9070, with a volume of 14,421,718 shares.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: HC Wainwright raised multi-year EPS forecasts (FY2027–FY2030) and keeps a “Buy” rating with a $10 price target, signaling improved earnings expectations that could support upside over the medium term. ImmunityBio (NASDAQ:IBRX) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Traders appear to be taking profits after a roughly two-week rally, which produced a short-term pullback in the share price rather than a fundamental reversal; this is a common swing-trading reaction after concentrated gains. ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run
• Neutral Sentiment: Liquidity and technicals show heavy recent trading and a wide 52-week range; elevated volume and a rebound off the low can amplify moves in either direction, increasing volatility risk for short-term holders. MarketBeat IBRX quote and metrics
• Negative Sentiment: Pomerantz LLP issued an investor alert announcing an investigation into ImmunityBio, introducing potential litigation and governance risk that could weigh on sentiment and increase downside pressure if the inquiry escalates. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. – IBRX

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. BTIG Research boosted their price target on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Piper Sandler boosted their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. HC Wainwright increased their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday. D. Boral Capital reissued a “buy” rating and set a $24.00 price objective on shares of ImmunityBio in a research report on Tuesday, January 20th. Finally, Jefferies Financial Group raised their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.80.

ImmunityBio Stock Performance

The firm’s fifty day moving average is $3.05 and its two-hundred day moving average is $2.67. The company has a market cap of $5.82 billion, a P/E ratio of -14.41 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to the consensus estimate of $31.88 million. On average, equities research analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Insider Activity at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 151,967 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the sale, the director owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 226,967 shares of company stock worth $1,531,912. Company insiders own 69.48% of the company’s stock.

Institutional Trading of ImmunityBio

Large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new stake in ImmunityBio in the second quarter worth $20,497,000. AlphaCore Capital LLC purchased a new stake in shares of ImmunityBio in the second quarter valued at approximately $7,854,000. Geode Capital Management LLC grew its stake in ImmunityBio by 34.7% in the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock worth $15,254,000 after purchasing an additional 1,487,849 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in ImmunityBio during the 2nd quarter worth $70,000. Finally, Blair William & Co. IL raised its position in ImmunityBio by 2.7% during the 2nd quarter. Blair William & Co. IL now owns 239,814 shares of the company’s stock valued at $633,000 after purchasing an additional 6,314 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.